What do systematic reviews say?

Dopamine vs norepinephrine

Dopamine showed no clear difference in total mortalitya compared with norepinephrine (high certainty).

• Vasopressors for hypotensive shock 2016 · Cochrane Headline outcomes only
  RR 1.07 [0.99, 1.16]
  6 studies · 1400 participants
  High

Dopamine vs norepinephrine

Dopamine leads to higher arrhythmia < BR/> compared with norepinephrine (high certainty).

• Vasopressors for hypotensive shock 2016 · Cochrane Headline outcomes only
  RR 2.33 [1.45, 3.85]
  2 studies · 1931 participants
  High

Dopamine‐milrinone vs dopamine‐dobutamine

It is very uncertain whether dopamine‐milrinone changes all‐cause short‐term mortality: at intensive care unit compared with dopamine‐dobutamine (very low certainty).

• Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
  RR 1 [0.34, 2.93]
  1 study · 20 participants
  Very low

Dopamine‐milrinone vs dopamine‐dobutamine

The review found no eligible studies for this question.

• Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dopamine agonist vs placebo or no intervention

Dopamine agonist probably leads to lower incidence of moderate or severe OHSS compared with placebo/no intervention (moderate certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.32 [0.23, 0.44]
  10 studies · 1202 participants
  Moderate

Dopamine agonist vs other active intervention

It is very uncertain whether dopamine agonist changes incidence of moderate or severe OHSS compared with other active intervention (very low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.21 [0.12, 0.38]
  3 studies · 296 participants
  Very low

Dopamine agonist vs other active intervention

Dopamine agonist showed no clear difference in live birth rate compared with other active intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 1.08 [0.73, 1.59]
  2 studies · 430 participants
  Low

Dopamine agonist vs other active intervention

Dopamine agonist showed no clear difference in clinical pregnancy rate compared with other active intervention (moderate certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 1.04 [0.81, 1.33]
  7 studies · 1060 participants
  Moderate

Dopamine agonist vs other active intervention

Dopamine agonist showed no clear difference in multiple pregnancy rate compared with other active intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.87 [0.47, 1.59]
  3 studies · 400 participants
  Low

Dopamine agonist vs other active intervention

Dopamine agonist showed no clear difference in miscarriage rate compared with other active intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.66 [0.35, 1.25]
  4 studies · 630 participants
  Low

Dopamine agonist vs other active intervention

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 170 participants
  GRADE not reported

Dopamine agonist vs placebo or no intervention

Dopamine agonist showed no clear difference in live birth rate compared with placebo/no intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.96 [0.6, 1.55]
  3 studies · 362 participants
  Low

Dopamine agonist vs placebo or no intervention

Dopamine agonist showed no clear difference in clinical pregnancy rate compared with placebo/no intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.92 [0.63, 1.37]
  5 studies · 530 participants
  Low

Dopamine agonist vs placebo or no intervention

It is very uncertain whether dopamine agonist changes multiple pregnancy rate compared with placebo/no intervention (very low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.32 [0.01, 8.26]
  1 study · 40 participants
  Very low

Dopamine agonist vs placebo or no intervention

Dopamine agonist showed no clear difference in miscarriage rate compared with placebo/no intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.66 [0.19, 2.28]
  2 studies · 168 participants
  Low

Dopamine agonist vs placebo or no intervention

It is very uncertain whether dopamine agonist changes any other adverse events compared with placebo/no intervention (very low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 4.54 [1.49, 13.84]
  2 studies · 264 participants
  Very low

Dopamine agonist vs placebo

Any dopamine agonist showed no clear difference in dropouts compared with placebo (moderate certainty).

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  RR 1.04 [0.94, 1.14]
  20 studies · 1656 participants
  Moderate

Dopamine agonist vs placebo

Any dopamine agonist showed no clear difference in adverse events as N of participants with at least one adverse event compared with placebo (moderate certainty).

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  RR 1.27 [0.66, 2.44]
  7 studies · 252 participants
  Moderate

Dopamine agonist vs placebo

Any dopamine agonist showed no clear difference in abstinence (objective) Participants abstinent at the end of… compared with placebo (low certainty).

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  RR 1.12 [0.85, 1.47]
  11 studies · 731 participants
  Low

Dopamine agonist vs placebo

Any dopamine agonist showed no clear difference in abstinence at compared with placebo (low certainty).

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  RR 1.1 [0.61, 1.98]
  4 studies · 136 participants
  Low